The future of Duchenne muscular dystrophy gene therapy: Shrinking the dystrophin gene

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 4, 2002, Pages 343-348

  Roberts, Michael L ^a   Dickson, George ^b  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AAV; Adenoviral vectors; Duchenne muscular dystrophy; Dystrophin; Hybrid vectors; Retroviral vectors

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DYSTROPHIN; GAG PROTEIN; POL PROTEIN; RETROVIRUS VECTOR; SPECTRIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; GENE CONSTRUCT; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; MOLECULAR CLONING; MOUSE; MUSCLE ATROPHY; NONHUMAN; PATHOGENESIS; REVIEW; STRUCTURE ACTIVITY RELATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; DYSTROPHIN; FORECASTING; GENE THERAPY; GENETIC VECTORS; HUMANS; HYBRIDIZATION, GENETIC; MICE; MUSCULAR DYSTROPHY, DUCHENNE; RETROVIRIDAE; SEQUENCE DELETION; SPECTRIN;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0036705303     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Emery AE: Duchenne muscular dystrophy - Meryon's disease. Neuromuscul Disord (1993) 3:263-266.
2. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE, Wilson JM: Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med (1997) 3:306-312.
3. Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, Sloan B, Cohen LK, Danos O: Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther (1997) 8:1891-1900.
4. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, Bulman DE, Harris JB, Davies KE: Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature (1990) 343:180-182.
5. Dunckley MG, Wells DJ, Walsh FS, Dickson G: Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Genet (1993) 2:717-723.
6. Vincent N, Ragot T, Gilgenkrantz H, Couton D, Chafey P, Gregoire A, Briand P, Kaplan JC, Kahn A, Perricaudet M: Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet (1993) 5:130-134.
7. Acsadi G, Lochmuller H, Jani A, Huard J, Massie B, Prescott S, Simoneau M, Petrof BJ, Karpati G: Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther (1996) 7:129-140.
8. Fassati A, Wells DJ, Sgro Serpente PA, Walsh FS, Brown SC, Strong PN, Dickson G: Genetic correction of dystrophin deficiency and skeletal muscle remodelling in adult MDX mouse via transplantation of retroviral producer cells. J Clin Invest (1997) 100:620-628.
9. Yuasa K, Miyagoe Y, Yamamoto K, Nabeshima Y, Dickson G, Takeda S: Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett (1998) 425:329-336.
10. Wang B, Li J, Xiao X: Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA (2000) 97:13714-13719.
11. Rafael JA, Cox GA, Corrado K, Jung D, Campbell KP, Chamberlain JS: Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol (1996) 134:93-102.
12. Fabb SA, Wells DJ, Serpente P, Dickson G: Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet (2002) 11:733-741.
13. Winnard AV, Klein CJ, Coovert DD, Prior T, Papp A, Snyder P, Bulman DE, Ray PN, McAndrew P, King W: Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. Hum Mol Genet (1993) 2:737-744.
14. Passos-Bueno MR, Vainof M, Marie SK, Zatz M: Half the dystrophin gene is apparently enough for a mild clinical course: Confirmation of its potential use for gene therapy. Hum Mol Genet (1994) 3:919-922.
15. Mirabella M, Galluzzi G, Manfredi G, Bertini E, Ricci E, De Leo R, Tonali P, Servidei S: Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy. Neurology (1998) 51:592-595.
16. Chelly J, Gilgenkrantz H, Lambert M, Hamard G, Chafey P, Recan D, Katz P, de la Chappelle A, Koenig M, Ginjaar IB: Effects of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell (1990) 63:1239-1248.
17. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM: Exploring the molecular basis for variability among patients with Becker muscular dystrophy: Dystrophin gene and protein studies. Am J Hum Genet (1991) 49:54-67.
18. McCabe ER, Towbin J, Chamberlain J, Baumbach L, Witkowski J, van Ommen GJ, Koenig M, Kunkel LM, Seltzer WK: Complementary DNA probes for the Duchenne, muscular dystrophy locus demonstrate a previously undetectable deletion in a patient with dystrophic myopathy, glycerol kinase deficiency, and congenital adrenal hypoplasia. J Clin Invest (1989) 83:95-99.
19. Muntoni F, Gobbi P, Sewry C, Sherrat T, Taylor J, Sandhu SK, Abbs S, Roberts R, Hodgson SV, Bobrow M, Dubowitz V: Deletions in the 5′ region of dystrophin and resulting phenotypes. J Med Genet (1994) 31:843-847.
20. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA Chamberlain JS: Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet (1995) 4:1251-1258.
21. Corrado K, Rafael JA, Mills PL, Cole NM, Faulkner JA, Wang K, Chamberlain JS: Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a 'mild Becker' phenotype. J Cell Biol (1996) 134:873-884.
22. Sakamoto M, Yuasa K, Yoshimura M, Yokota T, Ikemoto T, Suzuki M, Dickson G, Miyagoe-Suzuki Y, Takeda S: Microdystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun (2002) 293:1265-1272.
23. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV, Chamberlain JS: Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med (2002) 8:253-261.
24. Cross RA, Stewart M, Kendrick-Jones J: Structural predictions for the central domain of dystrophin. FEBS Letts (1990) 262:87-92.
25. Kahana E, Marsh PJ, Henry AJ, Way M, Gratzer WB: Conformation and phasing of dystrophin structural repeats. J Mol Biol (1994) 235:1271-1277.
26. Kahana E, Gratzer WB: Minimal folding unit of dystrophin rod domain. Biochemistry (1995) 34:8110-8114.
27. Dickson G, Roberts ML, Wells DJ, Fabb SA: Recombinant micro-genes and dystrophin viral vectors. Neuromuscul Disord (2002): in press.
28. Duisit G, Salvetti A, Moullier P, Cosset FL: Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum Gene Ther (1999) 10:189-200.
29. Roberts ML, Athanasopoulos T, Pohlschmidt M, Duisit G, Cosset FL, Dickson G: Post-mitotic, differentiated myotubes efficiently produce retroviral vector from hybrid adeno-retrovirus templates. Gene Ther (2001) 8:1580-1586.
30. Roberts ML, Wells DJ, Graham IR, Fabb SA, Hill VJ, Duisit G, Yuasa K, Takeda S, Cosset FL, Dickson G: Stable microdystrophin gene transfer using an integrating adenoretroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle. Hum Mol Genet (2002) 11:1719-1730.
31. Hodges BL, Serra D, Hu H, Begy CA, Chamberlain JS, Amalfitano A: Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med (2000) 2:250-259.